Archive
Every story, newest first.
Friday, November 13, 2026
Politics
The IAEA said in a new report that it is increasingly concerned about Iran's planned Isfahan Fuel Enrichment Plant, which it has never been allowed to inspect and whose exact location and contents it does not know.
Commodities
Brazil's first forecast for the 2027 grain harvest puts output at 346.6 million tonnes, down 2.6 percent from 2026, with corn down 5.6 percent and soy down 0.6 percent, the IBGE said on November 13.
Life Sciences
The European Medicines Agency's CHMP recommended seven new medicines for approval at its November 9 to 12 meeting, including Baxfendy (baxdrostat) for insufficiently controlled hypertension and two lung cancer medicines, Aumseqa and Zybrivo.
Infrastructure
The European Commission approved 286 million euros of German state aid for the port of Hamburg, two grants of 143 million euros each toward replacing the decayed walls of the Salzgitter and Steinwerder quays.
Infrastructure
Vertiv's board raised its regular annual dividend from 25 cents to 40 cents per share, the data centre power and cooling company said in a Form 8-K filed on November 13, starting with a 10 cent fourth quarter payment.
Rates
Italy's seasonally adjusted industrial production rose 1.2 percent in September from August, ISTAT reported, though third quarter output still fell 0.4 percent from the second quarter and production was 0.1 percent lower than a year earlier.
Tanker freight rose 5.45 percent by midday and Broadcom fell 5.14 percent, as Thursday's chip rotation reversed and the physical shipping squeeze tightened again.
Life Sciences
The Department of Health and Human Services on November 12 committed up to 4.9 million dollars through ARPA-H to prepare a United States made ibogaine product for PTSD trials, and posted a separate 20 million dollar funding opportunity for a research network on rapid acting psychotropic drugs.
Life Sciences
enGene said updated LEGEND trial data show a 56 percent complete response rate for detalimogene in BCG-unresponsive bladder cancer, with 43 percent of responses now estimated to last at least 12 months, and it will start its FDA filing by year end.
Life Sciences
The American Cancer Society on November 12 replaced its 2010 decide for yourself guidance with a direct recommendation: PSA blood tests every two years for average risk men aged 50 to 69, and annually from age 45 for Black men and men with a strong family history.